Verified
My legs felt less stiff during the morning, and I could stand from a chair more easily. The first week brought dry mouth and vivid dreams, so the timing was reviewed. The dreams became less intrusive after that.
30 Sep 2026
Amantadine
Quality products
24/7 Support
Fast delivery
Delivery
from 4 days
Active ingredient
Amantadine
Amantadine is a prescription medicine in the adamantane class. It is used for selected Parkinsonian symptoms and drug-induced movement disorders. It can improve motor function by increasing dopaminergic activity and modifying excitatory signalling in the brain.
Description
Amantadine is a prescription antiparkinsonian medicine in the adamantane class. It is used for Parkinsonian symptoms and some drug-induced movement disorders, while its older role against influenza A is limited by widespread viral resistance. Amantadine influences dopamine signalling in the brain and can improve motor function in selected patients.
Composition
Amantadine is an adamantane derivative used in neurology and infectious-disease pharmacology. The active pharmaceutical substance is amantadine, also called Adamantanamine Hydrochloride in chemical nomenclature. Amantadine Hydrochloride is the hydrochloride salt used in oral pharmaceutical preparations.
Amantadine belongs to the adamantanes, a group that includes antiviral compounds such as rimantadine. The same chemical family also has neurological applications because amantadine affects dopaminergic signalling within the central nervous system.
Active Ingredient and Pharmaceutical Identity
Amantadine Hydrochloride increases the water solubility of the active compound for oral administration. In clinical practice, physicians select the dose according to the indication, kidney function, age, concurrent medicines, and the formulation prescribed.
Kidney function changes how long amantadine remains in the body. A medication review should include renal disease, dialysis, and any recent change in kidney function before the dose is selected.
The medicine may be prescribed alone or as part of a wider Parkinson’s treatment plan. Patients should not change between immediate-release and extended-release formulations without a prescriber’s direction, because the release pattern changes drug exposure.
Dosage and usage
Practical administration principles include:
- Take the pills by mouth at the prescribed times.
- Swallow modified-release formulations whole.
- Do not crush, split, or chew an extended-release product unless the product-specific instructions explicitly permit it.
- Take missed doses when remembered unless the next scheduled dose is near.
- Do not double the next dose after a missed dose.
- Keep the daily schedule consistent, especially when Amantadine is combined with levodopa or carbidopa.
- Avoid abrupt discontinuation unless a prescriber gives a tapering or stopping plan.
If a pill causes vivid dreams or insomnia, the timing may need review. Do not move every dose independently; record the symptom and discuss the schedule with the clinician managing the Parkinson’s regimen.
Renal impairment deserves special attention. Amantadine is cleared mainly through the kidneys, so accumulation can produce confusion, hallucinations, muscle jerks, or marked dizziness. Older adults may experience toxicity even when the prescribed regimen has not recently changed.
How it works
Amantadine has two clinically relevant pharmacological actions. In Parkinsonian disorders, it increases dopaminergic activity by promoting dopamine release and reducing dopamine reuptake in certain brain pathways. It also has activity at N-methyl-D-aspartate receptors, which may reduce excessive excitatory signalling associated with dyskinesia.
Dopamine is a neurotransmitter involved in movement, motivation, attention, and reward. In Parkinson’s disease, loss of dopamine-producing neurons in the substantia nigra disrupts motor circuits in the basal ganglia. By increasing available dopamine, Amantadine may reduce slowness, rigidity, and some medication-related involuntary movements in selected patients.
The effect is not identical to levodopa. Levodopa supplies a precursor that the brain converts into dopamine, while Amantadine modifies dopamine release and glutamatergic signalling. This distinction explains why neurologists may use the medicines together rather than treating them as interchangeable options.
The FDA describes amantadine extended-release products as treatments for levodopa-induced dyskinesia in adults with Parkinson’s disease. The same regulatory material also describes renal dosing considerations and neuropsychiatric adverse reactions [1].
Amantadine’s antiviral action involves interference with the M2 ion channel of influenza A viruses. Resistance became widespread, which is why adamantane antivirals have a restricted role in modern influenza management.
Indications
Amantadine is used mainly for neurological indications. The clinical goal depends on whether symptoms arise from idiopathic Parkinson’s disease, secondary parkinsonism, or treatment-related dyskinesia.
| Clinical use | Intended treatment goal | Clinical context |
|---|---|---|
| Parkinsonian symptoms | Improve rigidity, bradykinesia, and movement initiation | Idiopathic or secondary parkinsonism |
| Levodopa-induced dyskinesia | Reduce troublesome involuntary movements | Parkinson’s disease treated with dopaminergic therapy |
| Drug-induced movement disorders | Ease selected extrapyramidal symptoms | Requires assessment of the causative medicine |
Idiopathic Parkinson’s disease is the most familiar indication. Amantadine may also be considered in post-encephalitic parkinsonism, carbon monoxide-induced parkinsonism, and other secondary movement disorders when a neurologist judges dopaminergic treatment appropriate.
Drug-induced extrapyramidal symptoms can include muscle stiffness, tremor, restlessness, and abnormal postures. The responsible medicine may need adjustment as well, because adding Amantadine without addressing the cause can leave the underlying problem unresolved.
The antiviral indication requires separate consideration. Amantadine was used for prevention and treatment of influenza A, but WHO influenza guidance has reported widespread resistance among circulating influenza A strains, limiting its routine role for this purpose [2]. It should not be treated as a general remedy for seasonal influenza or other respiratory viruses.
Comparison
The best alternative depends on the therapeutic target. Parkinson’s symptoms, levodopa-induced dyskinesia, and influenza prevention require different pharmacological strategies.
| Category | Main mechanism | Typical clinical role |
|---|---|---|
| Amantadine | Dopaminergic modulation and NMDA-receptor activity | Parkinsonian symptoms and selected dyskinesia |
| Carbidopa / levodopa | Converts levodopa into dopamine while carbidopa limits peripheral breakdown | Core treatment for motor symptoms in Parkinson’s disease |
| Oseltamivir or zanamivir | Neuraminidase inhibition | Influenza treatment or prevention when clinically indicated |
Rimantadine belongs to the same adamantane antiviral group as Amantadine, but resistance limits this class for influenza A. Oseltamivir and zanamivir act through a different antiviral mechanism and are considered in contemporary influenza management when treatment or prophylaxis is indicated.
Memantine is pharmacologically related through NMDA-receptor activity, yet it is used for a different neurological purpose. It should not be substituted for Amantadine without a clear clinical reason.
Carbidopa/levodopa may provide stronger dopaminergic replacement for bradykinesia and rigidity, while Amantadine may be selected when dyskinesia becomes a significant problem. Combination treatment can be useful, but it also increases the need to monitor dizziness, hallucinations, sleep disturbance, and involuntary movements.
Contraindications
Amantadine is not appropriate for everyone. It requires careful assessment in people with:
- Severe renal impairment or dialysis.
- A history of seizures.
- Psychosis, severe confusion, or uncontrolled hallucinations.
- Untreated narrow-angle glaucoma.
- Recurrent falls or pronounced orthostatic hypotension.
- Significant cardiac disease or a known prolonged QT interval.
- Previous serious allergic reaction to amantadine.
Pregnancy and breastfeeding require an individual benefit–risk assessment. The medicine may cross into breast milk, and the clinical reason for treatment should be clear before use during lactation.
Anticholinergic medicines can intensify dry mouth, constipation, blurred vision, urinary retention, confusion, and hallucinations. Examples include diphenhydramine and benztropine. Memantine may also add central nervous system effects because both medicines influence excitatory neurotransmission.
Other medicines that can increase dizziness, sedation, confusion, or falls deserve review. Alcohol may worsen impaired coordination and mental changes. Diuretics and medicines that alter electrolytes may matter when cardiac rhythm risk is present.
Bring a complete list of prescription medicines, over-the-counter products, and sleep or allergy tablets to a medication review. Diphenhydramine is easy to overlook because it may be used for short-term allergy or sleep symptoms.
The prescribing information identifies renal impairment, anticholinergic burden, neuropsychiatric reactions, and interactions affecting cardiac rhythm as important safety considerations [4].
When this is not for you
NOT for you if severe renal impairment, uncontrolled hallucinations, or serious rhythm risk cannot be safely managed.
Side effects
Amantadine can cause neurological, cardiovascular, gastrointestinal, and skin-related adverse effects. The likelihood rises when blood concentrations become excessive or when other medicines produce similar effects.
Common or clinically recognised reactions include:
- Nausea, reduced appetite, constipation, or dry mouth.
- Dizziness, light-headedness, and orthostatic hypotension.
- Insomnia, vivid dreams, agitation, or anxiety.
- Confusion, hallucinations, or changes in concentration.
- Peripheral ankle or leg oedema.
- Livedo reticularis, a mottled purplish skin pattern caused by altered small-vessel blood flow.
- Blurred vision and headache.
Livedo reticularis is often painless, yet it should be reported if it is new, extensive, or accompanied by swelling. Peripheral oedema also deserves assessment because it may reflect the medicine, venous disease, or a separate cardiac or renal problem.
Serious reactions include severe confusion, psychosis, seizures, fainting, dangerous heart-rhythm disturbance, and severe allergic reactions. The risk of hallucinations and delirium is higher in older people, patients with Parkinson’s-related cognitive impairment, and people with reduced renal clearance.
A patient may feel more alert or mobile while still having impaired balance. That distinction matters. Improved movement does not remove the risk of falls, especially during the first days of treatment or after a dose change.
Stand up slowly after sitting or lying down. Amantadine-related orthostatic symptoms may be most noticeable when rising at night, when poor lighting adds to fall risk.
Amantadine can also worsen impulse-control problems or trigger unusual behaviour in susceptible patients. New gambling, compulsive shopping, excessive sexual behaviour, or unexplained spending should be reported promptly.
The FDA prescribing information lists hallucinations, peripheral oedema, livedo reticularis, orthostatic hypotension, and falls among clinically relevant adverse reactions associated with amantadine products [3].
Common mistakes
Several avoidable problems can reduce benefit or increase adverse effects:
- Taking an extra pill after a missed dose.
- Crushing a modified-release formulation.
- Stopping treatment suddenly after months of use.
- Using sedating allergy tablets without considering anticholinergic effects.
- Ignoring ankle swelling or mottled skin changes.
- Assuming hallucinations are part of ageing or Parkinson’s disease and not reporting them.
- Forgetting to mention kidney disease or dialysis.
- Drinking alcohol when dizziness or confusion has already appeared.
- Measuring success only by tremor while overlooking dyskinesia, walking speed, and falls.
One practical mistake is changing the administration time every day in response to symptoms. That makes it difficult to identify whether the problem comes from the dose, the timing, another medicine, or the disease itself.
What doctors say
In clinical practice, neurologists often introduce Amantadine when motor symptoms remain troublesome despite an established Parkinson’s regimen or when levodopa-related dyskinesia interferes with daily activities. The expected benefit is usually functional rather than dramatic: walking may become easier, stiffness may lessen, or involuntary movements may become less disruptive.
Doctors also pay attention to cognition. A patient with mild memory problems may tolerate Amantadine, while someone with hallucinations or fluctuating attention may deteriorate quickly after exposure. Renal function can change the treatment decision even when the neurological indication is reasonable.
The medication should be judged by observable outcomes. Useful measures include time spent walking independently, frequency of dyskinesia, falls, sleep quality, and the ability to perform daily tasks. A symptom diary can show whether improvement lasts through the day or appears only at certain dosing times.
Clinicians may reduce or stop Amantadine gradually rather than suddenly, especially after long-term use. Abrupt withdrawal has been associated with worsening Parkinsonian symptoms, confusion, agitation, or other withdrawal-related changes [5].
Frequently asked questions
Is Amantadine used for Parkinson’s disease?
Amantadine is used for selected Parkinsonian symptoms and levodopa-induced dyskinesia. The FDA label was revised in 2017. Treatment goals should be agreed with the prescribing clinician. The FDA’s amantadine prescribing information describes its role in adults with Parkinson’s disease and dyskinesia, with renal adjustment when required. The clinical decision depends on symptoms, cognition, falls, kidney function, and the rest of the treatment plan.
Does Amantadine increase dopamine?
Amantadine can increase dopaminergic activity by promoting dopamine release and reducing reuptake in relevant neural pathways. The mechanism is described in pharmacology references used by the National Library of Medicine (2024) and remains distinct from the dopamine replacement provided by levodopa. Benefits may involve movement initiation, rigidity, or dyskinesia rather than every Parkinson’s symptom.
How long does Amantadine take to work?
Some patients notice changes in movement or dyskinesia within days, while others require longer observation before the effect is clear. Parkinson’s Foundation educational material published in 2024 recommends judging treatment by function, symptom patterns, and adverse effects rather than by a single day. A sudden lack of benefit or new confusion requires prompt review of the regimen.
Can Amantadine be taken with levodopa?
Amantadine may be prescribed alongside levodopa and carbidopa when the clinical goal is to improve motor control or reduce dyskinesia. The FDA describes extended-release amantadine products as an option for adults receiving levodopa-based treatment in its 2017 prescribing information. The combination can also increase dizziness, hallucinations, sleep disturbance, or involuntary movement changes, so the schedule should remain clinician-directed.
Does Amantadine prevent influenza?
Amantadine has antiviral activity against influenza A, but resistance has limited its routine use. WHO influenza guidance published in 2024 does not support relying on adamantanes for routine seasonal influenza control because resistant strains are widespread. Amantadine should not be used as a substitute for an indicated contemporary antiviral or seasonal vaccination.
Can Amantadine cause hallucinations?
Hallucinations and confusion are recognised adverse effects, with greater risk in older adults, people with cognitive impairment, and patients whose kidneys clear the medicine slowly. The FDA drug label identifies neuropsychiatric reactions as a safety concern in its 2017 prescribing information. New visions, voices, severe agitation, or disorientation require urgent clinical assessment rather than self-directed dose changes.
What happens if an Amantadine dose is missed?
A missed dose should generally be taken when remembered unless the next scheduled dose is close. The FDA patient information advises avoiding two doses at the same time in its 2017 prescribing information. A repeated pattern of missed doses can make symptoms fluctuate, so the timing problem should be addressed through a practical routine rather than compensatory dosing.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Comparison
Compare all medications for AntiviralsAmantadine: Reviews and Experiences
3.4
Based on 4 reviews
Verified
The involuntary movements after levodopa reduced enough for me to eat more comfortably. I still had occasional ankle swelling, and the benefit was not the same every day. Keeping a simple movement diary helped show the neurologist the pattern.
10 Oct 2026
Verified
I became confused at night and saw figures in the room. I had assumed it was part of Parkinson’s disease, but the symptoms improved after the treatment plan was changed. Kidney function was checked during the review.
21 Oct 2026
Verified
Walking felt slightly easier, but sleep was poor when I took the pills too late. Moving the timing under medical direction helped. The medicine did not remove every symptom.
28 Oct 2026
Sources
- U.S. Food and Drug Administration (2017). GOCOVRI (amantadine) extended-release capsules prescribing information.
- World Health Organization (2024). Influenza: antiviral treatment and resistance information.
- U.S. Food and Drug Administration (2017). GOCOVRI Clinical Pharmacology and Adverse Reactions.
- National Library of Medicine (2024). Amantadine: MedlinePlus Drug Information.
- European Medicines Agency (2017). Guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease.
